JZL184

CAS No. 1101854-58-3

JZL184 ( JZL184; JZL 184; JZL-184 )

Catalog No. M17810 CAS No. 1101854-58-3

JZL 184 is a potent and selective inhibitor of MAGL with IC50 of 8 nM and 4 μM for inhibition of MAGL and FAAH in mouse brain membranes respectively.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 31 In Stock
10MG 49 In Stock
25MG 104 In Stock
50MG 197 In Stock
100MG 357 In Stock
200MG 482 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JZL184
  • Note
    Research use only, not for human use.
  • Brief Description
    JZL 184 is a potent and selective inhibitor of MAGL with IC50 of 8 nM and 4 μM for inhibition of MAGL and FAAH in mouse brain membranes respectively.
  • Description
    JZL184 is highly selective, and potent MAGL inhibitor ( monoacylglycerol lipase inhibitor). JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome. JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. JZL184 also suppresses inflammatory pain in the mouse carrageenan model.
  • Synonyms
    JZL184; JZL 184; JZL-184
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    MAGL
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    1101854-58-3
  • Formula Weight
    520.49
  • Molecular Formula
    C27H24N2O9
  • Purity
    98%
  • Solubility
    DMSO : ≥ 35 mg/mL; 67.24 mM
  • SMILES
    OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+](=O)[O-])(c1ccc2OCOc2c1)c1ccc2OCOc2c1
  • Chemical Name
    4-nitrophenyl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate.

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Long JZ, et al. Nat Chem Biol, 2009, 5(1), 37-44.
molnova catalog
related products
  • EGFRvIII peptide PEP...

    PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.

  • VPC-18005

    VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.

  • WAY-604116

    WAY-604116 has anti-inflammatory, antitumor and antiasthmatic effects.